Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
Recruiting · NCT06753981 · Observational (researchers observe without assigning treatment) · Lead sponsor: Qianfoshan Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
What this trial is about
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Consent and sign the informed consent form
- Non-low-risk PAH treatment-naive patients
Exclusion criteria
- Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
- Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
- Pregnant or lactating women
- Suffering from mental illness or cognitive impairment
- PAH patients with concurrent malignant tumors
- Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
- Currently participating in other interventional clinical studies
- Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.
Where it is running
1 location listed.
- Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China - Jinan, Shandong, China